Zobrazeno 1 - 10
of 131
pro vyhledávání: '"Yuji Hori"'
Autor:
Yuji Hori, Ken Ohmine, Hitoshi Katada, Yuki Noguchi, Kazuki Sato, Takeru Nambu, Lam Runyi Adeline, Gan Siok Wan, Kenta Haraya, Kazuhisa Ozeki, Masahiko Nanami, Tatsuhiko Tachibana, Zenjiro Sampei, Taichi Kuramochi, Junichi Nezu, Kunihiro Hattori, Tomoyuki Igawa
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
A conventional antibody targeting a soluble antigen in circulation typically requires a huge dosage and frequent intravenous administration to neutralize the antigen. This is because antigen degradation is reduced by the formation of antigen–antibo
Externí odkaz:
https://doaj.org/article/664a7d33da584019aead7576585d2286
Autor:
Hiroyasu Muramatsu, Taichi Kuramochi, Hitoshi Katada, Atsunori Ueyama, Yoshinao Ruike, Ken Ohmine, Meiri Shida-Kawazoe, Rie Miyano-Nishizawa, Yuichiro Shimizu, Momoko Okuda, Yuji Hori, Madoka Hayashi, Kenta Haraya, Nobuhiro Ban, Tatsuya Nonaka, Masaki Honda, Hidetomo Kitamura, Kunihiro Hattori, Takehisa Kitazawa, Tomoyuki Igawa, Yoshiki Kawabe, Junichi Nezu
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
Abstract Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeuti
Externí odkaz:
https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c
Autor:
Yoko Yoshida, Masanori Matsumoto, Hideo Yagi, Ayami Isonishi, Kazuya Sakai, Masaki Hayakawa, Yuji Hori, Toshiyuki Sado, Hiroshi Kobayashi, Yoshihiro Fujimura
Publikováno v:
Blood Advances, Vol 1, Iss 20, Pp 1628-1631 (2017)
Externí odkaz:
https://doaj.org/article/482cba960240427baa01ce9299307dd1
Autor:
Taku Fukuzawa, Zenjiro Sampei, Kenta Haraya, Yoshinao Ruike, Meiri Shida-Kawazoe, Yuichiro Shimizu, Siok Wan Gan, Machiko Irie, Yoshinori Tsuboi, Hitoshi Tai, Tetsushi Sakiyama, Akihisa Sakamoto, Shinya Ishii, Atsuhiko Maeda, Yuki Iwayanagi, Norihito Shibahara, Mitsuko Shibuya, Genki Nakamura, Takeru Nambu, Akira Hayasaka, Futa Mimoto, Yuu Okura, Yuji Hori, Kiyoshi Habu, Manabu Wada, Takaaki Miura, Tatsuhiko Tachibana, Kiyofumi Honda, Hiroyuki Tsunoda, Takehisa Kitazawa, Yoshiki Kawabe, Tomoyuki Igawa, Kunihiro Hattori, Junichi Nezu
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract Dysregulation of the complement system is linked to the pathogenesis of a variety of hematological disorders. Eculizumab, an anti-complement C5 monoclonal antibody, is the current standard of care for paroxysmal nocturnal hemoglobinuria (PNH
Externí odkaz:
https://doaj.org/article/84b20be1cd2e48b4b4a92b1de12240c0
Autor:
Sebiha Cevik, Anna A W M Sanders, Erwin Van Wijk, Karsten Boldt, Lara Clarke, Jeroen van Reeuwijk, Yuji Hori, Nicola Horn, Lisette Hetterschijt, Anita Wdowicz, Andrea Mullins, Katarzyna Kida, Oktay I Kaplan, Sylvia E C van Beersum, Ka Man Wu, Stef J F Letteboer, Dorus A Mans, Toshiaki Katada, Kenji Kontani, Marius Ueffing, Ronald Roepman, Hannie Kremer, Oliver E Blacque
Publikováno v:
PLoS Genetics, Vol 9, Iss 12, p e1003977 (2013)
Cilia are microtubule-based cell appendages, serving motility, chemo-/mechano-/photo- sensation, and developmental signaling functions. Cilia are comprised of distinct structural and functional subregions including the basal body, transition zone (TZ
Externí odkaz:
https://doaj.org/article/566785b284434b95974086b530bbc77f
Autor:
Masanori Matsumoto, Charles L Bennett, Ayami Isonishi, Zaina Qureshi, Yuji Hori, Masaki Hayakawa, Yoko Yoshida, Hideo Yagi, Yoshihiro Fujimura
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e33029 (2012)
Thrombotic thrombocytopenic purpura (TTP) is a type of thrombotic microangiopathy (TMA). Studies report that the majority of TTP patients present with a deficiency of ADAMTS13 activity. In a database of TMA patients in Japan identified between 1998 a
Externí odkaz:
https://doaj.org/article/1f87713093bc45e8b5c825bc5fdb8c69
Autor:
Tomoyuki Igawa, Takehisa Kitazawa, Yoshiki Kawabe, Kou-ichi Jishage, Mika Endo, Yoshito Nakanishi, Otoya Ueda, Atsuhiko Kato, Noriaki Sawada, Yasushi Tomii, Fumihisa Isomura, Masaki Kamimura, Tetsuya Wakabayashi, Ami Ito, Haruka Kuroi, Junko Shinozuka, Yuki Noguchi, Motohiko Sato, Yasuko Satoh, Nasa Savory, Sotaro Naoi, Koki Hamada, Ayano Hirako, Sayuri Horikawa, Akihisa Sakamoto, Shun-ichiro Komatsu, Shojiro Kadono, Tomochika Matsushita, Tetsushi Sakiyama, Kenji Adachi, Natsuki Ono, Tatsuhiko Tachibana, Hirofumi Mikami, Shun Shimizu, Yuki Ohte, Naoko A. Wada, Taro Miyazaki, Shoichi Metsugi, Meiri Shida-Kawazoe, Kenji Taniguchi, Naoka Hironiwa, Masaki Honda, Ryo Uchikawa, Takayuki Nemoto, Yuji Hori, Yoshinori Narita, Mika Kamata-Sakurai
Supplementary figures, tables, material and methods, and references
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef075e9b136326aba4e8a3303859f52
https://doi.org/10.1158/2159-8290.22535753.v1
https://doi.org/10.1158/2159-8290.22535753.v1
Autor:
Kyoko Fukushima, Rie Hantani, Shiori Naruoka, Yukiyo Toyonaga, Yuji Hori, Koichi Aoyagi, Hiroshi Yamanaka, Susumu Miyazaki, Atsuo Tanimoto, Seiji Kawashita, Yoshiji Hantani
Publikováno v:
Chemical Biology & Drug Design. 98:914-929
The development of small molecule inhibitors of programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) has drawn research interest for the treatment of cancer. Recently, we reported the discovery of a novel dimeric core small molecule PD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::901084d28a5ea32c80e28dbe5751de50
https://doi.org/10.1111/cbdd.13949
https://doi.org/10.1111/cbdd.13949
Autor:
Tatsuhiko Tachibana, Nasa Savory, Otoya Ueda, Sayuri Horikawa, Tetsushi Sakiyama, Tomochika Matsushita, Yuji Hori, Kou-ichi Jishage, Haruka Kuroi, Motohiko Sato, Tetsuya Wakabayashi, Junko Shinozuka, Naoka Hironiwa, Meiri Shida-Kawazoe, Kenji Adachi, Ryo Uchikawa, Taro Miyazaki, Koki Hamada, Masaki Honda, Fumihisa Isomura, Mika Endo, Mika Kamata-Sakurai, Yoshito Nakanishi, Yuki Noguchi, Natsuki Ono, Yasuko Satoh, Yuki Ohte, Tomoyuki Igawa, Ayano Hirako, Hirofumi Mikami, Naoko A. Wada, Noriaki Sawada, Takehisa Kitazawa, Yasushi Tomii, Shun-ichiro Komatsu, Takayuki Nemoto, Yoshinori Narita, Kenji Taniguchi, Shun Shimizu, Naoi Sotaro, Akihisa Sakamoto, Shojiro Kadono, Yoshiki Kawabe, Atsuhiko Kato, Kamimura Masaki, Shoichi Metsugi, Ami Ito
Publikováno v:
Cancer Discovery. 11:158-175
Agonistic antibodies targeting CD137 have been clinically unsuccessful due to systemic toxicity. Because conferring tumor selectivity through tumor-associated antigen limits its clinical use to cancers that highly express such antigens, we exploited
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a70e3edd07d12527043287be739925bc
https://doi.org/10.1158/2159-8290.cd-20-0328
https://doi.org/10.1158/2159-8290.cd-20-0328
Autor:
Meiri Shida-Kawazoe, Yoshinao Ruike, Kenta Haraya, Nobuhiro Ban, Ken Ohmine, Tomoyuki Igawa, Atsunori Ueyama, Hiroyasu Muramatsu, Yuji Hori, Yuichiro Shimizu, Rie Miyano-Nishizawa, Takehisa Kitazawa, Masaki Honda, Madoka Hayashi, Jun-ichi Nezu, Hidetomo Kitamura, Yoshiki Kawabe, Kunihiro Hattori, Momoko Okuda, Taichi Kuramochi, Tatsuya Nonaka, Hitoshi Katada
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
Scientific Reports
Scientific Reports
Myostatin, a member of the transforming growth factor-b superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::951076f88a18bafedc95a3adae225315
https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c
https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c